中国药房2018，Vol.29Issue(9)：1281-1287,7.DOI:10.6039/j.issn.1001-0408.2018.09.32
玉屏风散联合第二代抗组胺药对比第二代抗组胺药治疗慢性荨麻疹有效性及安全性的Meta分析
Meta-analysis of Efficacy and Safety of Yupingfeng Powder Combined with Second-generation Antihistamines Versus Second-generation Antihistamines for Chronic Urticaria
摘要
Abstract
OBJECTIVE:To evaluate the efficacy and safety of Yupingfeng powder combined with second- generation antihistamines versus second-generation antihistamines for chronic urticaria(CU)systematically,and to provide evidence-based reference for clinical treatment for CU. METHODS:Retrieved from PubMed,Embase,The Cochrane Library,CJFD,VIP and CBM,RCT about therapeutic efficacy(total response rate,cure rate,recurrence rate)and safety(the incidence of ADR)of Yupingfeng combined with second-generation antihistamines(trial group)versus second-generation antihistamines(control group) in the treatment of CU were collected. The data extraction was performed for included clinical studies,and Meta-analysis was performed by using Rev Man 5.3 statistical software after quality evaluation with Cochrane Handbook 5.1.0 evaluation criteria. RESULTS:A total of 34 RCTs were enrolled,involved 3 405 patients in total. Results of Meta-analysis showed that the total response rate [OR=4.02,95%CI(3.03,5.34),P<0.001],cure rate [OR=2.25,95%CI(1.95,2.60),P<0.001] and recurrence rate [OR=0.33,95%CI(0.26,0.42),P<0.001] of trial group were significantly better than those of control group,with statistical significance. There was no statistical significance in the incidence of ADR between 2 groups [OR=0.98,95%CI(0.71,1.37),P=0.92]. CONCLUSIONS:For CU therapy,Yupingfeng powder combined with second-generation antihistamines is better than second-generation antihistamines alone in improving total response rate and cure rate,reducing recurrence rate,both have similar safety.关键词
玉屏风散/慢性荨麻疹/第二代抗组胺药/Meta分析Key words
Yupingfeng powder/Chronic urticaria/Second-generation antihistamines/Meta-analysis分类
医药卫生引用本文复制引用
田梦菲,李文林,杨丽丽,黄莹,连紫宇,曹青青,马妍婷,王雅洁,陈涤平..玉屏风散联合第二代抗组胺药对比第二代抗组胺药治疗慢性荨麻疹有效性及安全性的Meta分析[J].中国药房,2018,29(9):1281-1287,7.基金项目
国家自然科学基金资助项目(No.81373843) （No.81373843）
江苏省中医药局科技项目(No.YB2015002) （No.YB2015002）
